Aon PLC vs Charles River Laboratories Intl. Inc — how do they compare? Aon PLC trades at $352.26 (market cap $75.61B), while Charles River Laboratories Intl. Inc trades at $287.33 (market cap $13.46B). The key difference: Aon PLC is far larger — about 5.6× Charles River Laboratories Intl. Inc's market cap, and Aon PLC pays a 0.92% dividend while Charles River Laboratories Intl. Inc pays none. Which is the better fit depends on your goals.
| AON | CRL | |
|---|---|---|
Market Cap | $75.61B | $13.46B |
Sector | Financials | Health |
52-Week High | $381.26 | $282.00 |
52-Week Low | $308.22 | $145.57 |
Enterprise Value | $90.22B | $16.30B |
Dividend Yield | 0.92% | — |
Signals from Pluang's Aura AI — not financial advice
AON trades at $351.56, down 1.52% on the day, with a neutral technical signal and strong fundamentals including a 22.27% net income margin and consistent earnings beats. The stock shows robust profitability with ROE of 44.88% and revenue growth to $17.18B in 2025, though valuation multiples like a P/E of 19.65 and P/S of 4.37 reflect premium pricing. Recent news highlights institutional buying and Q2 2026 earnings beat, with organic revenue growth of 5% supporting positive sentiment.
Outlook remains favorable given earnings momentum and analyst consensus price target of $410, but risks include high valuation sensitivity and debt levels. The stock offers growth exposure with upside potential, balanced by execution risks in a competitive insurance brokerage sector.
Charles River Laboratories (CRL) trades at $286.36, up 3.38% today and near its 52-week high of $277.07. The stock shows strong technical momentum with bullish moving averages and has beaten earnings estimates for three consecutive quarters. Recent Q2 2026 results exceeded expectations with EPS of $3.02 versus $2.77 estimate, driving positive sentiment. However, valuation metrics remain elevated with P/E at 684.85 and negative profitability margins.
While technical indicators and analyst consensus (72% buy ratings) support near-term upside, fundamental concerns persist with negative net income margin (-5.96%) and ROE (-7.7%). The stock faces execution risks in maintaining earnings momentum amid competitive pressures. Current price exceeds consensus target of $277.29, suggesting limited near-term upside potential despite positive business inflection.
Trailing returns across standard periods
Latest headlines on both assets
Aon is a leading global provider of insurance and reinsurance brokerage and human resource solutions. Its operations are tilted toward its brokerage operations. Headquartered in London, Aon has about 50,000 employees and operations in 120 countries around the world.
Read more on AON →Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →